1. Home
  2. QUIK vs TLSI Comparison

QUIK vs TLSI Comparison

Compare QUIK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuickLogic Corporation

QUIK

QuickLogic Corporation

HOLD

Current Price

$12.98

Market Cap

314.2M

Sector

Technology

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.27

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUIK
TLSI
Founded
1988
2010
Country
United States
United States
Employees
51
102
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
314.2M
270.2M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
QUIK
TLSI
Price
$12.98
$4.27
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$11.00
$7.00
AVG Volume (30 Days)
450.5K
448.5K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,112,000.00
N/A
Revenue This Year
$75.17
$35.45
Revenue Next Year
$16.04
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.80
$2.20
52 Week High
$24.33
$7.95

Technical Indicators

Market Signals
Indicator
QUIK
TLSI
Relative Strength Index (RSI) 31.21 54.13
Support Level $11.59 $4.27
Resistance Level $23.39 $4.38
Average True Range (ATR) 1.19 0.31
MACD -0.44 -0.02
Stochastic Oscillator 9.94 53.62

Price Performance

Historical Comparison
QUIK
TLSI

About QUIK QuickLogic Corporation

QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: